Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA User Fees Offer Good And Bad News For Sponsors In FY 2020

Executive Summary

Prescription drug user fees increase as many generic and biosimilar fees drop, as illustrated in our infographic.

You may also be interested in...



User Fee Delinquencies Rising At US FDA After PDUFA Redesign

Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.

US FDA Priority Review Voucher Fee Continues Drop In FY 2020

Sponsors will pay 12% less to redeem a voucher in FY 2020, which is charged on top of the traditional PDUFA user fee.

PDUFA Workload Sets Records, But Inflation Generates More Revenue

The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS140620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel